Dealbook – With corporate breakups on Wall Street’s mind, one of the biggest activist hedge fund managers around thinks the maneuver could prove helpful for the drug giant Amgen.
Third Point, the hedge fund run by Daniel S. Loeb, suggested on Tuesday that the drug maker should consider splitting itself into two businesses: a faster-growing entity whose products require heavy amounts of research spending, nicknamed GrowthCo; and a slower-growing company with more mature products that can afford to pay out a hefty dividend, known as MatureCo.
